Fulcrum Therapeutics Shares Outstanding 2018-2021 | FULC

Fulcrum Therapeutics shares outstanding from 2018 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Fulcrum Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 25
2019 11
2018 1
2017 1
Fulcrum Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 33
2021-03-31 32
2020-12-31 25
2020-09-30 27
2020-06-30 24
2020-03-31 23
2019-12-31 11
2019-09-30 18
2019-06-30 2
2019-03-31 2
2018-12-31 1
2018-09-30 1
2018-06-30 1
2018-03-31 1
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.078B $0.009B
Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71